natgillin/translations-raw huggingface dataset:
Den populationsfarmakokinetiske analyse tydede på, at samtidig infektion med hepatitis B- og/eller Cvirus ikke havde nogen klinisk relevant effekt på eksponeringen for rilpivirin. 
Population pharmacokinetic analysis indicated that hepatitis B and/or C virus co-infection had no clinically relevant effect on the exposure to rilpivirine.
Ikke almindelige: - symptomer på betændelsestilstand eller infektion, f.eks. feber, kulderystelser, svedeture 
Uncommon: - signs or symptoms of inflammation or infection, for example fever, chills, sweats (immune reactivation syndrome)
Tabel 5: Resistensreultater ud fra det anvendte NRTI-baggrundsregime (poolede data fra studierne ECHO og THRIVE i resistensanalysen i uge 96) tenofovir/ emtricitabin zidovudin/ lamivudin abacavir/ lamivudin 
Resistance outcome by background NRTI regimen used (pooled data from the ECHO and THRIVE trials in the week 96 resistance analysis) tenofovir/ emtricitabine zidovudine/ lamivudine abacavir/ lamivudine
Hos patienter med viral load ≤ 100.000 kopier/ml ved baseline udviste 9 ud af 27 patienter med virologisk svigt på rilpivirin behandlingsudviklet resistens over for rilpivirin (ved genotypeanalyse) med følgende hyppighed af fænotypekrydsresistens: etravirin 4/9, efavirenz 3/9 og nevirapin 1/9. 
In patients with a baseline viral load ≤ 100,000 copies/ml, 9 out of 27 patients with virologic failure on rilpivirine showed treatment-emergent resistance to rilpivirine (genotypic analysis), with the following frequency of phenotypic cross-resistance: etravirine 4/9, efavirenz 3/9, and nevirapine 1/9.
Der foreslås ikke dosisjustering, men forsigtighed tilrådes hos patienter med moderat nedsat leverfunktion. 
No dose adjustment is suggested but caution is advised in patients with moderate hepatic impairment.
Rilpivirin hæmmer transportøren MATE-2K in vitro med en IC50 < 2,7 nM. 
Rilpivirine is an in vitro inhibitor of the transporter MATE-2K with an IC50 of < 2.7 nM.
Genotypisk resistens bør være vejledende for brugen af EDURANT (se pkt. 
Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1).
EDURANT bør anvendes med forsigtighed til denne population (se pkt. 
EDURANT should be used with caution in this population (see section 4.2).
ANTACIDA Antacida (f.eks. aluminium- eller magnesiumhydroxid, calciumcarbonat) 
ANTACIDS Antacids (e.g., aluminium or magnesium hydroxide, calcium carbonate)
Der forventes signifikante fald i rilpivirins plasmakoncentration. 
Significant decreases in rilpivirine plasma concentrations are expected.
Hos behandlingsnaive unge forsøgspersoner 
In treatment-naïve adolescent subjects
De hyppigst observerede resistensassocierede mutationer, der opstod, omfattede L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C og M230I. 
The most commonly observed resistance-associated mutations that emerged included L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C and M230I.
EDURANT 25 mg filmovertrukne tabletter 
EDURANT 25 mg film-coated tablets
Patienter med en viral load ved baseline på > 100.000 hiv 1-RNA-kopier/ml, som oplevede virologisk svigt, udviste en større rate af resistens opstået efter behandlingsstart over for klassen af non-nukleosid reverse transcriptasehæmmere (NNRTI). 
Patients with a baseline viral load > 100,000 HIV-1 RNA copies/ml who experienced virologic failure exhibited a higher rate of treatment-emergent resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
Yderligere behandlingstiltag bør bygge på de kliniske tegn eller følge anbefalingerne fra Giftlinjen, om muligt. 
Further management should be as clinically indicated or as recommended by the national poisons centre, where available.
Samtidig behandling med rilpivirin og dabigatranetexilat bør ske med forsigtighed. 
The combination of rilpivirine and dabigatran etexilate should be used with caution.
Hiv-NNRTI NNRTI (delavirdin, efavirenz, etravirin, nevirapin) 
HIV NNRTIs NNRTIs (delavirdine, efavirenz, etravirine, nevirapine)
ANTIBIOTIKA MED VIRKNING PÅ MYKOBAKTERIER Rifabutin* 
ANTIMYCOBACTERIALS Rifabutin*
Der var ingen nye forekomster vedrørende sikkerhed sammenlignet med den kendte sikkerhedsprofil for rilpivirin hos hiv-1inficerede voksne (se pkt. 
There were no new safety findings compared with the known safety profile of rilpivirine in HIV-1 infected adults (see sections 4.2, 4.4 and 5.2).
I nedenstående tabel 4 vises resultaterne af analyser efter 48 uger og 96 uger for patienter behandlet med rilpivirin og patienter behandlet med efavirenz fra de poolede data fra studierne ECHO og THRIVE. 
Table 4 below shows the results of the week 48 and the week 96 efficacy analysis for patients treated with rilpivirine and patients treated with efavirenz from the pooled data from the ECHO and THRIVE trials.
Af de patienter, der var responders i uge 96, havde 74 % af de patienter, der fik rilpivirin, fortsat udetekterbar viral load (< 50 hiv 1-RNA-kopier/ml) i uge 240 sammenlignet med 81 % af de patienter, der fik efavirenz. 
Of those patients who were responders at week 96, 74% of patients receiving rilpivirine remained with undetectable viral load (< 50 HIV-1 RNA copies/ml) at week 240 compared to 81% of patients receiving efavirenz.
Farmakokinetik, sikkerhed, tolerabilitet og virkning af rilpivirin 25 mg én gang dagligt i kombination med et investigator-valgt BR med to NRTI'er blev evalueret i TMC278-C213-studiet, et enkeltarmet, åbent fase II-studie med antiretroviral-naive hiv 1-inficerede unge forsøgspersoner, der vejede mindst 
The pharmacokinetics, safety, tolerability and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, was evaluated in trial TMC278-C213, a single-arm, open-label Phase II trial in antiretroviral treatment-naïve HIV-1 infected adolescent subjects weighing at least 32 kg.
Samtidig behandling med rilpivirin og en H2-receptorantagonist bør ske med ekstra forsigtighed. 
The combination of rilpivirine and H2-receptor antagonists should be used with particular caution.
Hiv-proteasehæmmere - uden samtidig indgift af lavdosis ritonavir Ikke-boostede PI (atazanavir, fosamprenavir, indinavir, nelfinavir) 
HIV PIs - without co-administration of low dose ritonavir Unboosted PIs (atazanavir, fosamprenavir, indinavir, nelfinavir)
I betragtning af alle de tilgængelige in vitro- og in vivo-data hos behandlingsnaive forsøgspersoner kan følgende resistensassocierede mutationer påvirke aktiviteten af rilpivirin, når de er til stede ved baseline: K101E, K101P, E138A, E138G, E138K, E138R, E138Q, V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I og M230L. 
Considering all of the available in vitro and in vivo data in treatment-naïve subjects, the following resistance-associated mutations, when present at baseline, may affect the activity of rilpivirine: K101E, K101P, E138A, E138G, E138K, E138R, E138Q, V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I, and M230L.
3 om, hvordan du skal tage EDURANT: "Vejledning i brug til voksne og unge (fra 12 til under 18 år)". 
EDURANT, please carefully read how to take EDURANT in section 3 “Instructions for proper use in adults and adolescents (12 to less than 18 years of age)”.
Samtidig brug af EDURANT og azol-antimykotika kan øge plasmakoncentrationen af rilpivirin. 
Concomitant use of EDURANT with azole antifungal agents may cause an increase in the plasma concentrations of rilpivirine.
Der kræves ingen dosisjustering af EDURANT til ældre patienter (se pkt. 
No dose adjustment of EDURANT is required in older patients (see section 5.2).
EDURANT 25 mg filmovertrukne tabletter rilpivirin 
EDURANT 25 mg film-coated tablets rilpivirine
En populationsfarmakokinetisk analyse af rilpivirin hos hiv-inficerede patienter viste, at etnisk tilhørsforhold ikke havde nogen klinisk relevant effekt på eksponeringen for rilpivirin. 
Population pharmacokinetic analysis of rilpivirine in HIV infected patients indicated that race had no clinically relevant effect on the exposure to rilpivirine.
(reduceret absorption pga. stigning i gastrisk pH) H2-RECEPTORANTAGONISTER Famotidin* 40 mg enkeltdosis taget 12 timer før rilpivirin rilpivirin AUC ↓ 9 % rilpivirin Cmin IR rilpivirin Cmax ↔ 
(reduced absorption due to gastric pH increase) H2-RECEPTOR ANTAGONISTS Famotidine* 40 mg single dose taken 12 hours before rilpivirine rilpivirine AUC ↓ 9% rilpivirine Cmin NA rilpivirine Cmax ↔
Forsøgspersonerne opnåede virologisk respons (to konsekutive virale belastninger < 50 kopier/ml) og opretholdt respons til og med uge 48 og uge 240. 
Subjects achieved virologic response (two consecutive viral loads < 50 copies/ml) and maintained it through week 48 and week 240.
EDURANT skal tages i forbindelse med et måltid. 
EDURANT must be taken with a meal.
6 celler/l). 
6 cells/l).
6 celler/l) 
6 cells/l)
Andre NRTI'er (abacavir, emtricitabin, lamivudin, stavudin og zidovudin) 
Other NRTIs (abacavir, emtricitabine, lamivudine, stavudine and zidovudine)
Til patienter med svært nedsat nyrefunktion eller terminal nyresygdom bør kombinationen af rilpivirin og en stærk CYP3A-hæmmer (f.eks. en ritonavir-boostet hiv-proteasehæmmer) kun anvendes, hvis fordelen opvejer risikoen (se pkt. 
In patients with severe renal impairment or end-stage renal disease, the combination of rilpivirine with a strong CYP3A inhibitor (e.g., ritonavir-boosted HIV protease inhibitor) should only be used if the benefit outweighs the risk (see section 5.2).
Medianvarigheden af eksponering var henholdsvis 104,3 og 104,1 uger hos patienterne i rilpivirin-gruppen og efavirenz-gruppen. 
The median duration of exposure for patients in the rilpivirine arm and efavirenz arm was 104.3 and 104.1 weeks, respectively.
Hos patienter i samtidig behandling med rifabutin skal dosis af EDURANT øges til 50 mg (to tabletter a 25 mg) 1 gang dagligt. 
For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) taken once daily.
Der var flere patienter, som svigtede virologisk med rilpivirin, end patienter som svigtede virologisk med efavirenz, der udviklede lamivudin/emtricitabin associeret resistens (se pkt. 
More patients who failed virologically on rilpivirine than who failed virologically on efavirenz developed lamivudine/emtricitabine associated resistance (see section 5.1).
Rilpivirin bør ikke indgives samtidig med andre NNRTI. 
It is not recommended to co-administer rilpivirine with other NNRTIs.
Almindelige: - unormale drømme - udslæt - mavesmerter - depression - træthed - opkastning 
Common: - abnormal dreams - rash - stomach pain - depression - tiredness - vomiting - drowsiness - decreased appetite - sleep disorders - stomach discomfort - depressed mood - dry mouth
- cimetidin, famotidin, nizatidin, ranitidin (H2-receptorantagonister til behandling af mavesår eller sår på tarmen eller til lindring af halsbrand, der skyldes tilbageløb af syre). 
- clarithromycin, erythromycin (antibiotics) - cimetidine, famotidine, nizatidine, ranitidine (H2-receptor antagonists used to treat stomach or intestinal ulcers or used to relieve heartburn due to acid reflux).
Eftersom rilpivirin i høj grad er bundet til plasmaproteiner, er det usandsynligt, at stoffet vil kunne elimineres signifikant ved hæmodialyse eller peritonealdialyse (se pkt. 
As rilpivirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis (see section 4.2).
Hvis du har taget for mange tabletter, kan du få hovedpine, kvalme, svimmelhed og/eller unormale drømme. 
In case of overdose, you may have a headache, nausea, dizziness, and/or abnormal dreams.
Tag H2-receptorantagonisten mindst 12 timer før eller mindst 4 timer efter EDURANT (se "Brug af anden medicin sammen med EDURANT" under pkt. 
Take the H2-receptor antagonist at least 12 hours before or at least 4 hours after EDURANT (see section 2 “Other medicines and EDURANT”).
I den puljede effektanalyse efter 96 uger i fase III-studierne hos voksne havde patienter behandlet med rilpivirin, som havde en viral load på > 100.000 hiv 1-RNA-kopier/ml ved baseline, en større risiko for virologisk svigt (18,2 % med rilpivirin versus 7,9 % med efavirenz) sammenlignet med patienter med en viral load på ≤ 100.000 hiv 1-RNA-kopier/ml ved baseline (5,7 % med rilpivirin versus 3,6 % med efavirenz). 
In the pooled efficacy analysis from the Phase III trials in adults through 96 weeks, patients treated with rilpivirine with a baseline viral load > 100,000 HIV-1 RNA copies/ml had a greater risk of virologic failure (18.2% with rilpivirine versus 7.9% with efavirenz) compared to patients with a baseline viral load ≤ 100,000 HIV-1 RNA copies/ml (5.7% with rilpivirine versus 3.6% with efavirenz).
Behandlingsnaive hiv 1-inficerede voksne patienter Evidensen for effekten af rilpivirin er baseret på analyserne af data efter 96 uger fra 2 randomiserede, dobbeltblinde, aktivt kontrollerede fase III-studier, TMC278-C209 (ECHO) og TMC278-C215 (THRIVE). 
The evidence of efficacy of rilpivirine is based on the analyses of 96 week data from 2 randomised, double-blinded, active-controlled, Phase III trials TMC278-C209 (ECHO) and TMC278-C215 (THRIVE).
Indtagelse af EDURANT i fastende tilstand eller kun sammen med en ernæringsdrik kan reducere plasmakoncentrationen af rilpivirin, hvilket muligvis kan reducere den terapeutiske effekt af EDURANT (se pkt. 
Taking EDURANT in fasted condition or with only a nutritional drink may result in decreased plasma concentrations of rilpivirine, which could potentially reduce the therapeutic effect of EDURANT (see section 4.2).
Virologisk svigt i effektanalyse: Omfatter forsøgspersoner med rebound (konfirmeret viral belastning ≥ 50 kopier/ml efter respons) eller som aldrig var supprimerede (ingen konfirmeret viral belastning < 50 kopier/ml, enten i behandling eller efter seponering af behandling pga. manglende eller tabt virkning). 
Virologic failure in efficacy analysis: includes subjects who were rebounder (confirmed viral load ≥ 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load < 50 copies/ml, either ongoing or discontinued due to lack or loss of efficacy).
Manglende respons Virologisk svigt I alt 
Non-response Virologic failure
I den poolede resistensanalyse fra uge 48 i fase III-studierne havde 62 (ud af i alt 72) med virologiske svigt i rilpivirin-gruppen resistensdata ved baseline og på tidspunktet for svigt. 
In the week 48 pooled resistance analysis from the Phase III trials, 62 (of a total of 72) virologic failures in the rilpivirine arm had resistance data at baseline and time of failure.
Lactosemonohydrat Croscarmellosenatrium Povidon K30 
Lactose monohydrate Croscarmellose sodium Povidone K30
I studie TMC278-C204 blev der inkluderet 368 hiv 1-inficerede behandlingsnaive voksne patienter, som havde hiv 1-RNA ≥ 5.000 kopier/ml i plasma, tidligere havde fået ≤ 2 ugers behandling med en N(t)RTI eller proteasehæmmer, ikke tidligere havde taget NNRTI og blev screenet for følsomhed over for N(t)RTI og for fravær af specifikke NNRTI-resistensassocierede mutationer. 
Study TMC278-C204 enrolled 368 HIV-1 infected treatment-naïve adult patients who had a plasma HIV-1 RNA ≥ 5,000 copies/ml, previously received ≤ 2 weeks of treatment with an N(t)RTI or protease inhibitor, had no prior use of NNRTIs and were screened for susceptibility to N(t)RTI and for absence of specific NNRTI resistance-associated mutations.
Farmakokinetiske resultater for total-rilpivirin efter administration af rilpivirin 25 mg én gang daglig som del af et antiretroviralt regimen under graviditetens 2. trimester, 3. trimester og postpartum 
Pharmacokinetic Results of Total Rilpivirine After Administration of Rilpivirine 25 mg Once Daily as Part of an Antiretroviral Regimen, During the 2
Tenofovirdisoproxilfumarat* 
Tenofovir disoproxil fumarate*
Sikkerhedsvurderingen er baseret på analysen efter 48 uger af det åbne, enkeltarmede fase II-studie TMC278-C213, i hvilket 36 antiretroviral-naive hiv 1-inficerede unge patienter, der vejede mindst 32 kg, fik rilpivirin (25 mg én gang dagligt) i kombination med andre antiretrovirale midler (se pkt. 
The safety assessment is based on the week 48 analysis of the single-arm, open-label, Phase II trial, TMC278-C213, in which 36 antiretroviral treatment-naïve HIV-1 infected adolescent patients weighing at least 32 kg received rilpivirine (25 mg once daily) in combination with other antiretroviral agents (see section 5.1).
Virologisk svigt i poolet effektanalyse: Omfatter forsøgspersoner med rebound (konfirmeret viral load ≥ 50 kopier/ml efter respons) eller som aldrig var supprimerede (ingen konfirmeret viral load < 50 kopier/ml, enten i behandling eller efter seponering af behandling pga. manglende eller tab af virkning). 
Virologic failure in pooled efficacy analysis: includes subjects who were rebounder (confirmed viral load ≥ 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load < 50 copies/ml, either ongoing or discontinued due to lack or loss of efficacy).
Det virologiske respons blev generelt bevaret under hele studiet: Ud af de 12 forsøgspersoner, der gennemførte studiet, var der viral hæmning hos 10 forsøgspersoner ved slutningen af studiet. 
The virologic response was generally preserved throughout the study: of the 12 subjects that completed the study, 10 subjects were suppressed at the end of the study; in the other 2 subjects an increase in viral load was observed only postpartum, for at least 1 subject due to suspected suboptimal adherence.
Hvis du bemærker det efter 12 timer, skal du springe denne dosis over og derefter blot fortsætte med den sædvanlige dosis. 
If you notice after 12 hours, then skip that dose and take the next doses as usual.
Tabel 2: Bivirkninger rapporteret hos antiretroviral-naive hiv 1-inficerede voksne patienter behandlet med rilpivirin (poolede data fra analysen i uge 96 i fase III-studierne ECHO og THRIVE) N = 686 Systemorganklasse 
Table 2: ADRs reported in antiretroviral treatment-naïve HIV-1 infected adult patients treated with Rilpivirine (pooled data from the week 96 analysis of the Phase III ECHO and THRIVE trials) N=686 System Organ Class (SOC) Frequency Category ADRs (Rilpivirine + BR)
Rilpivirin + BR N = 686 
Rilpivirine + BR N=686
Rilpivirins farmakokinetiske egenskaber er ikke undersøgt hos patienter med nyreinsufficiens. 
The pharmacokinetics of rilpivirine have not been studied in patients with renal insufficiency.
Det er ikke sandsynligt, at rilpivirin i en dosis på 25 mg x 1 vil have en klinisk relevant effekt på eksponeringen for lægemidler, der metaboliseres af CYP-enzymer. 
Medicinal products that are affected by the use of rilpivirine Rilpivirine at a dose of 25 mg once daily is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
EDURANT bør anvendes med forsigtighed, når det indgives samtidigt med et lægemiddel med kendt risiko for torsades de pointes. 
EDURANT should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes.
Efter indgift som en enkelt peroral dosis af 
After single dose oral administration of
Median CD4+ celletal (interval), x 10 
Median baseline CD4+ cell count (range), x 10
Hos både han- og hunmus var rilpivirin positivt for hepatocellulære neoplasmer. 
In mice, rilpivirine was positive for hepatocellular neoplasms in both males and females.
Hvide til offwhite, filmovertrukne, runde, bikonvekse tabletter præget med "TMC" på den ene side og "25" på den anden side. 
What EDURANT looks like and contents of the pack White to off-white, film-coated, round, biconvex tablet, with “TMC” on one side and “25” on the other side.
Der pågår undersøgelser af rilpivirins farmakokinetiske egenskaber hos pædiatriske patienter under 12 år. 
The pharmacokinetics of rilpivirine in paediatric patients less than 12 years of age are under investigation.
PROTONPUMPEHÆMMERE Omeprazol* 
PROTON PUMP INHIBITORS Omeprazole*
Tag medicinen enten mindst 2 timer før eller mindst 4 timer efter EDURANT (se "Brug af anden medicin sammen med EDURANT" under pkt. 
Take the antacid either at least 2 hours before or at least 4 hours after EDURANT (see section 2 “Other medicines and EDURANT”).
Stigning i CD4+ celletal (middel) 
Increase in CD4+ cell count (mean)
Antacida bør kun indgives enten mindst 2 timer før eller mindst 4 timer efter rilpivirin. 
Antacids should only be administered either at least 2 hours before or at least 4 hours after rilpivirine.
Tabel 3: Sygdomskarakteristika ved baseline for antiretroviralnaive hiv 1-inficerede voksne forsøgspersoner i studierne ECHO og THRIVE (poolet analyse) 
Baseline disease characteristics of antiretroviral treatment-naïve HIV-1 infected adult subjects in the ECHO and THRIVE trials (pooled analysis)
Sygdomskarakteristika ved baseline Median hiv 1-RNA (interval), log10 kopier/ml i plasma ved baseline 
Baseline disease characteristics Median baseline plasma HIV-1 RNA (range), log10 copies/ml
Forsøgspersonerne opnåede virologisk respons (to konsekutive viral loads < 50 kopier/ml) og opretholdt respons til og med uge 48. 
Subjects achieved virologic response (two consecutive viral loads < 50 copies/ml) and maintained it through week 48/96.
Der forventes dosisafhængige fald i rilpivirins plasmakoncentration. 
Dose dependent decreases in rilpivirine plasma concentrations are expected.
I denne analyse var de resistensassocierede mutationer (RAM) forbundet med NNRTI-resistens, der blev udviklet i mindst 2 af tilfældene med virologisk svigt af rilpivirin, V90I, K101E, E138K, E138Q, V179I, Y181C, V189I, H221Y og F227C. 
In this analysis, the resistance-associated mutations (RAMs) associated with NNRTI resistance that developed in at least 2 rilpivirine virologic failures were: V90I, K101E, E138K, E138Q, V179I, Y181C, V189I, H221Y, and F227C.
Didanosin bør indgives mindst 2 timer før eller mindst 4 timer efter rilpivirin. 
Didanosine should be administered at least two hours before or at least four hours after rilpivirine.
Hvis du kaster op over 4 timer efter, at du har taget EDURANT, behøver du ikke at tage en tablet, før du skal tage den næste dosis til sædvanlig tid. 
If you vomit more than 4 hours after taking EDURANT you do not need to take another tablet until your next regularly scheduled tablet.
Antiretroviralnaive hiv 1-inficerede patienter, som havde hiv 1-RNA ≥ 5.000 kopier/ml i plasma og blev screenet for følsomhed over for N(t)RTI-præparater og for fravær af specifikke NNRTIresistensassocierede mutationer, blev inkluderet. 
Antiretroviral treatment-naïve HIV-1 infected patients were enrolled who had a plasma HIV-1 RNA ≥ 5,000 copies/ml and were screened for susceptibility to N(t)RTIs and for absence of specific NNRTI resistance-associated mutations.
Hvis opkastningen finder sted over 4 timer efter indtagelse af lægemidlet, behøver patienten ikke at tage en til dosis EDURANT før den næste planlagte dosis. 
If a patient vomits more than 4 hours after taking the medicine, the patient does not need to take another dose of EDURANT until the next regularly scheduled dose.
Zidovudin/lamivudin 
Zidovudine/lamivudine
4.4, 4.6, 5.1 og 5.2). 
Alternatively, switching to another ART regimen could be considered (see sections 4.4, 4.6, 5.1 and 5.2).
Behandling med rilpivirin Resistens 
Rilpivirine-treated Resistance
50 mg enkeltdosis sildenafil AUC ↔ sildenafil Cmin IR sildenafil Cmax ↔ rilpivirin AUC ↔ rilpivirin Cmin ↔ rilpivirin Cmax ↔ 
50 mg single dose sildenafil AUC ↔ sildenafil Cmin NA sildenafil Cmax ↔ rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↔
Interaktion Geometrisk middelværdi ændring 
Interaction Geometric mean change (%)
Hjælpestof, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 56 mg lactosemonohydrat. 
Excipient with known effect Each film-coated tablet contains 56 mg lactose monohydrate.
Samtidig indgift af rilpivirin og ritonavir-boostede PI øger plasmakoncentrationen af rilpivirin, men dosisjustering er ikke nødvendig. 
Concomitant use of rilpivirine with ritonavir-boosted PIs causes an increase in the plasma concentrations of rilpivirine, but no dose adjustment is required.